Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria-Reference-Cited by-同舟云学术

Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria

Published:2002-01 Issue:1 Volume:7 Page:11-18
ISSN:1360-2276
Container-title:Tropical Medicine and International Health
language:en
Short-container-title:Trop Med Int Health

Author:

Brieger William R.,Otusanya Sakiru A.,Oke Ganiyu A.,Oshiname Frederick O.,Adeniyi Joshua D.

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Parasitology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-3156.2002.00826.x/fullpdf

Reference15 articles.

1. 1 JD Adeniyi, M Sridhar, J Ramakrishna, and WR Brieger (1987 ) Nigerian students study water disease . World Water August 1987, 48 -49 .

2. 2 African Programme for Onchocerciasis Control (1998 )Community-Directed Treatment with Ivermectin (CDTI). A Practical Guide for Trainers of Community-Directed Distributors. APOC, Ouagadougou.

3. Delivery systems and cost Mectizan treatment for onchocerciasis recovery in

4. Gender and ethnic differences in onchocercal skin disease in Oyo State, Nigeria

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia;Parasites & Vectors;2024-03-15

2. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial;Malaria Journal;2024-02-22

3. Synthesis of findings from the literature and a qualitative research study on the impacts of gender, disability, and ethnicity in Neglected Tropical Diseases programs;PLOS Neglected Tropical Diseases;2023-12-04

4. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial;2023-11-15

5. O. volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: Results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia;2023-05-04